N-(3-phenylpropyl)-4-phenylbutylamine | 136534-65-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(3-phenylpropyl)-4-phenylbutylamine
• 英文别名: 4-phenyl-N-(3-phenylpropyl)butan-1-amine；N-(4-phenylbutyl)-3-phenylpropylamine；(4-phenyl-butyl)-(3-phenyl-propyl)-amine；(4-Phenyl-butyl)-(3-phenyl-propyl)-amin
• CAS: 136534-65-1
• 化学式: C₁₉H₂₅N
• 分子量: 267.414
• InChiKey: DPBLHNNYVNISFS-UHFFFAOYSA-N

物化性质

• 熔点：
  180 °C
• 沸点：
  402.7±34.0 °C(Predicted)
• 密度：
  0.974±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  20
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N-(3-phenylpropyl)-4-phenylbutylamine 、 formic acid-formaldehyde 以to form the starting material, N-methyl-N-(3-phenylpropyl)-4-phenylbutylamine的产率得到N-methyl-N-(3-phenylpropyl)-4-phenylbutylamine
  参考文献：
  名称：

  Quaternary ammonium antiarrhythmic drugs

  摘要：

  某些苯基丁基胺的季铵盐是有用的抗心律失常药物。提供了一种治疗心律失常和延长心脏组织作用电位的方法。公开了含有这种季铵盐的制药配方。

  公开号：

  US04289787A1
• 作为产物：
  描述：

  苯基-4-丁胺 、 1-氯-3-苯基丙烷 在 乙醇 、 sodium carbonate 作用下， 生成 N-(3-phenylpropyl)-4-phenylbutylamine
  参考文献：
  名称：

  Kuelz et al., Chemische Berichte, 1939, vol. 72, p. 2161,2166

  摘要：

  DOI：

文献信息

• Saturated heterocyclic carboxamide derivatives
  申请人：YAMANOUCHI PHARMACEUTICAL CO. LTD.

  公开号：EP0279681A2

  公开（公告）日：1988-08-24

  A saturated heterocyclic carboxamide derivative of the following general formula (I) and salts thereof which have platelet activating factor (PAF) antagonizing activity.

  具有血小板活化因子（PAF）拮抗活性的下式（I）饱和杂环羧酰胺衍生物及其盐类。
• Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure
  作者：Manoj Manickam、Hitesh B. Jalani、Thanigaimalai Pillaiyar、Niti Sharma、Pulla Reddy Boggu、Eeda Venkateswararao、You-Jung Lee、Eun-Seok Jeon、Sang-Hun Jung

  DOI：10.1016/j.ejmech.2017.04.005

  日期：2017.7

  A series of flexible urea derivatives have been synthesized and demonstrated as selective cardiac myosin ATPase activator. Among them 1-phenethyl-3-(3-phenylpropyl)urea (1, cardiac myosin ATPase activation at 10) mu M = 51.1%; FS = 18.90; EF = 12.15) and 1-benzyl-3-(3-phenylpropyl)urea (9, cardiac myosin ATPase activation = 53.3%; FS = 30.04; EF = 18.27) showed significant activity in vitro and in vivo. The change of phenyl ring with tetrahydropyran-4-yl moiety viz., 1-(3-phenylpropy1)-3-((tetrahydro-2H-pyran-4-y1) methyl)urea (14, cardiac myosin ATPase activation = 81.4%; FS = 20.50; EF = 13.10), and morpholine moiety viz., 1-(2-morpholinoethyl)-3-(3-phenylpropyl)urea (21, cardiac myosin ATPase activation = 44.0%; FS = 24.79; EF = 15.65), proved to be efficient to activate the cardiac myosin. The potent compounds 1, 9, 14 and 21 were found to be selective for cardiac myosin over skeletal and smooth myosins. Thus, these urea derivatives are potent scaffold to develop as a newer cardiac myosin activator for the treatment of systolic heart failure. (C) 2017 Elsevier Masson SAS. All rights reserved.
• Quaternary ammonium salts, and their formulations and preparation
  申请人：ELI LILLY AND COMPANY

  公开号：EP0002604B1

  公开（公告）日：1983-05-04
• SIGMA RECEPTOR LIGANDS AND THE USE THEREOF
  申请人：VIRGINIA COMMONWEALTH UNIVERSITY

  公开号：EP0507863A1

  公开（公告）日：1992-10-14
• EP0507863A4
  申请人：——

  公开号：EP0507863A4

  公开（公告）日：1993-07-07